| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1faa614d3f13cf78cbe7e7b081aa34cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef2e9f5ce8630d9b282043b8d060caff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5ac3316f8e8f9a90c7bc5f53ea103fe7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_caa9efbff4ab14abb7a93895c7b1b365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cdd9d06edad71566d710b51745b08f17 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-46 |
| filingDate |
2010-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdce7b9b7fe62f253066c9ee2c1fce06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42e349fc4e15a4f8c0e7603ba4f32f5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e914c83982298e70670f2f751f4fb727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72679834aa4560b2291d2eec22105d53 |
| publicationDate |
2012-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8168795-B2 |
| titleOfInvention |
Selective sphingosine-1-phosphate receptor antagonists |
| abstract |
Described herein are compounds useful as antagonists of sphingosine-1-phosphate receptors. Further described herein is the use of these compounds and related pharmaceutical compositions to treat disorders associated with sphingosine-1-phosphate-3 (S1P3) receptor modulation. |
| priorityDate |
2009-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |